A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection-Reference-Cited by-同舟云学术

A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection

Published:2022-09-28 Issue:18 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Ao Zhujun¹²,Ouyang Maggie J.¹²,Olukitibi Titus A.¹²,Warner Bryce³,Vendramelli Robert³,Truong Thang³,Meilleur Courtney³,Zhang Manli⁴,Kung Sam⁴,Fowke Keith R.²,Kobasa Darwyn²³,Yao Xiaojian¹²^ORCID

Affiliation:

1. Laboratory of Molecular Human Retrovirology, University of Manitoba, Winnipeg, Manitoba, Canada

2. Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

3. Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada

4. Department of Immunology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Abstract

Given that both COVID-19 and influenza are preferably transmitted through respiratory droplets during the same seasons, it is highly advantageous to develop a bivalent vaccine that could simultaneously protect against both COVID-19 and influenza. In this study, we generated the attenuated replicating recombinant vesicular stomatitis virus (rVSV)-based vaccine candidates that target both spike protein of SARS-Cov-2 Delta variant and the conserved influenza M2 domain.

Funder

Gouvernement du Canada | Canadian Institutes of Health Research

Research Manitoba

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.01337-22

Reference66 articles.

1. Looking beyond COVID-19 vaccine phase 3 trials

2. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape